Prostamax Research Guide: Khavinson Tetrapeptide Bioregulator
Prostamax is a Khavinson-class tetrapeptide bioregulator (Lys-Glu-Asp-Pro) studied for tissue-specific gene expression effects in prostate research.
What is Prostamax?
Prostamax is one of dozens of tissue-specific short peptide bioregulators developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson program isolates 2–4 residue sequences from specific tissues and produces synthetic versions for research.
Mechanism of action
The proposed mechanism — supported primarily by Russian research literature — involves direct peptide-DNA interaction at histone-tail sites, resulting in tissue-specific transcriptional modulation. Prostamax is targeted to prostate tissue and studied in the context of age-related prostate gene expression changes.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is Prostamax?
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) belonging to the Khavinson class of short peptide bioregulators — a Russian research lineage that isolates tissue-specific short peptides thought to modulate gene expression.
Mechanism?
Khavinson-class peptides are proposed to enter cells and bind directly to DNA histone tails, modulating chromatin accessibility and tissue-specific gene expression. Prostamax is characterized specifically for prostate tissue.